Everything below concerns lyophilized powder. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Last reviewed on 2026-05-07. Where a claim depends on a specific study, the study is described rather than over-claimed.
Direct human evidence is scarce. One trial in ulcerative colitis delivered the compound by enema and produced limited publicly reported results without a clear benefit. The compound is not an approved medicine in most jurisdictions. In many markets it is sold as a research chemical; in others it falls under prescription or controlled categories. Regulators have not confirmed any claimed medical use, and product labels rarely undergo premarket review.
Most published reports describe experiments in rodents rather than in people. These studies examine outcomes in tendons, ligaments, bone, stomach lining, and intestinal tissue. In rat and mouse models, a frequently reported effect is faster healing or reduced damage. Sample sizes are usually small, and a substantial share of the work originates from a small number of research groups. Independent replication is limited, so how far the findings extend to humans remains an open question.
Published work on BPC-157 spans several decades and covers a wide range of experimental models. Much of the early literature reports outcomes in animal studies involving induced injury to the gastrointestinal tract, tendons, and other tissues. The volume of preclinical reports is large, while controlled human trials remain scarce. This imbalance is a recurring point of discussion, because animal findings do not automatically translate into human effects. Reviews often note that study designs differ substantially across laboratories.
Interest in the peptide has grown through online communities that discuss self-administered use, which sits outside formal research settings. Regulatory status varies by country, and in many jurisdictions the compound is not approved as a therapeutic product. Questions about optimal routes of administration, long-term effects, and dose-response relationships remain open. Published pharmacokinetic data in humans are limited, and much of what circulates in popular discussion is extrapolated from animal work rather than measured directly in people.
BPC-157 is a synthetic peptide built from fifteen amino acids, referred to in the literature as a pentadecapeptide. Its sequence was derived from a larger protein found in human gastric juice, commonly called body protection compound. Researchers first described the fragment in the early 1990s and named it after the parent protein plus a numeric identifier. The peptide does not correspond to a single marketed medicine; it is primarily a laboratory research material. Suppliers distribute it as a lyophilized powder intended for experimental use.
| Property | Value | Notes |
|---|---|---|
| Main study model | Rodents, rats and mice | Underpins most of the published data |
| Common routes in studies | Subcutaneous, intraperitoneal, oral | Varies with the experimental design |
| Common analytical method | Reversed-phase HPLC, LC-MS | Used for identity and purity checks |
| Human evidence base | Small | Few trials reported, with limited findings |
| Regulatory status | Varies by jurisdiction | Not an approved medicine in most places |
Common synonyms in catalogs include pentadecapeptide BPC 157, BPC157, and the full sequence name. A CAS registry number in the 137525-51-0 range is frequently listed, though the assignment should be verified against the supplier certificate of analysis. The name itself is not a pharmacopoeial designation, and there is no standardized international nonproprietary name. Distinguishing genuine material from related fragments generally requires mass spectrometry, since several truncated sequences share similar chromatographic behavior.
BPC-157 is a synthetic pentadecapeptide whose sequence is commonly given as Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val. It is described in the literature as a fragment of a larger protein found in human gastric juice, referred to as body protection compound. The peptide was first characterized in the early 1990s by a research group in Zagreb, Croatia. Its molecular formula is C62H98N16O22 and its monoisotopic mass is approximately 1419 daltons.
Lyophilized material is generally kept cold, commonly at minus twenty degrees Celsius, and shielded from moisture and light. Solutions are less stable than the dry powder, so repeated freeze-thaw cycles are avoided by splitting the material into single-use portions. Published stability data for this particular peptide are limited, which means suggested hold times should be read as provisional. Long-term refrigeration of reconstituted solutions is not well supported by available evidence.
Identity and purity are checked with standard peptide techniques. Reversed-phase high-performance liquid chromatography separates the main peak from closely related impurities and yields a percentage purity. Mass spectrometry confirms that the measured mass matches the theoretical value. Amino acid analysis offers an independent check on overall composition. These analytical methods characterize the material itself and reveal nothing about how it behaves in a living system.
Confirmation of identity and purity relies on standard peptide analysis techniques. Reverse-phase high-performance liquid chromatography separates the peptide from related impurities and serves as the most common purity assay. Mass spectrometry, often coupled to that chromatography step, provides an accurate molecular mass that can be matched against the expected value. Amino acid analysis or sequencing can be added for further confirmation. Because short peptides can be produced by different synthetic routes, laboratories usually report both a chromatographic purity percentage and a mass confirmation rather than a single figure.
BPC-157 is commonly supplied as a lyophilized powder, a freeze-dried solid that is reconstituted before use in laboratory work. As a short peptide, it dissolves readily in water and in aqueous buffer solutions, and stock solutions are typically prepared in water or a mild buffer. The chain contains several proline and acidic residues, which influence how it behaves in solution. Because the solid can take up moisture, weighing and handling are usually performed under low-humidity conditions. Its solubility class is described as freely soluble in water rather than requiring an organic solvent.
It is also being investigated for use in removing contaminants from drinking water. Nano Silver: Nano Silver is being incorporated into textiles, clothing, food packaging, and other materials to eliminate bacteria. EPA and the U.S. Consumer Product Safety Commission are studying certain products to see whether they transfer nano-size silver particles in real-world scenarios. EPA is researching this topic to better understand how much nano-silver children come in contact with in their environments. Iron: While nano-scale iron is being investigated for many uses, including "smart fluids" for uses such as optics polishing and as a better-absorbed iron nutrient supplement, one of its more prominent current uses is to remove contamination from groundwater. This use, supported by EPA research, is being piloted at a number of sites across the United States.
Pyrimidine nucleosides include cytidine, uridine, and thymidine. The synthesis of pyrimidine nucleotides begins with the formation of uridine monophosphate (UMP). This process requires aspartate, glutamine, bicarbonate, and two molecules of ATP to provide energy. Additionally, phosphoribosyl pyrophosphate (PRPP) provides the ribose-phosphate backbone. Unlike purine synthesis, in which the nitrogenous base is built upon PRPP, pyrimidine synthesis forms the base first and attaches it to PRPP later in the process. Once UMP is synthesized, it undergoes phosphorylation using ATP to form uridine-triphosphate (UTP). UTP can then be converted into cytidine-triphosphate (CTP) in a reaction catalyzed by CTP synthetase, which utilizes glutamine as an amine donor. The synthesis of thymidine nucleotides requires the reduction of UMP to deoxyuridine monophosphate (dUMP) via ribonucleotide reductase (see next section). dUMP is then methylated by thymidylate synthase to produce thymidine monophosphate (TMP). The regulation of pyrimidine synthesis is tightly controlled. ATP, a purine nucleotide, activates pyrimidine synthesis, while CTP, a pyrimidine nucleotide, acts as an inhibitor. This regulatory feedback ensures balanced purine and pyrimidine levels, which is essential for DNA and RNA synthesis. Deficiencies in enzymes involved in pyrimidine synthesis can lead to metabolic disorders such as orotic aciduria.
== Clinical trials == On 7 March 2024, the company announced the results from the Phase I trial of the pill form of amycretin. In January 2025, the company announced the results of its 1B/2A trial. The trial investigated safety, tolerability, and pharmacokinetics following weekly subcutaneous administration in 125 patients. Treatment duration was up to 36 weeks. Novo Nordisk Chief Executive Lars Fruergaard Jørgensen forecast the roll-out of amycretin to be largely injectable medicines at first with oral versions being introduced later in higher-priced markets.
==== By ions ==== Upon illumination of the chloroplasts, the pH of the stroma rises from 7.0 to 8.0 because of the proton (hydrogen ion, H+) gradient created across the thylakoid membrane. The movement of protons into thylakoids is driven by light and is fundamental to ATP synthesis in chloroplasts (Further reading: Photosynthetic reaction centre; Light-dependent reactions). To balance ion potential across the membrane, magnesium ions (Mg2+) move out of the thylakoids in response, increasing the concentration of magnesium in the stroma of the chloroplasts. RuBisCO has a high optimal pH (can be >9.0, depending on the magnesium ion concentration) and, thus, becomes "activated" by the introduction of carbon dioxide and magnesium to the active sites as described above.
Sources: en.wikipedia.org
=== Surgical anatomy for nasal reconstruction === The human nose is a sensory organ that is structurally composed of three types of tissue: (i) an osseo-cartilaginous support framework (nasal skeleton), (ii) a mucous membrane lining, and (iii) an external skin. The anatomic topography of the human nose is a graceful blend of convexities, curves, and depressions, the contours of which show the underlying shape of the nasal skeleton. Hence, these anatomic characteristics permit dividing the nose into nasal subunits: (i) the midline (ii) the nose-tip, (iii) the dorsum, (iv) the soft triangles, (v) the alar lobules, and (vi) the lateral walls. Surgically, the borders of the nasal subunits are ideal locations for the scars, whereby is produced a superior aesthetic outcome, a corrected nose with corresponding skin colors and skin textures.
== Operations == A&W is the only major fast-food chain in the United States to be owned entirely by franchisees since the 2011 sale from Yum! Brands to A Great American Brand, LLC., which is mostly under the control of the National A&W Franchisee Association (NAWFA). The current owners rely heavily on single-brand restaurants, in contrast to combined, co-branded restaurants, which came from prior administrations. As of December 2021, there were 900 restaurants in the US and Asia. In the United States alone, the states with the most restaurants are California, followed by Wisconsin and Michigan. As of year-end 2023, A&W has 455 franchised restaurants in the US market alone. The number of co-branded locations has been on the decline with 243 such units. As of January 2025, A&W has made it to the Franchise 500 list for six consecutive years, standing at 210th place in the 2024 ranking. The number of restaurants in the United States and in Asia is almost equiparable, with the chain steadily decreasing its number of units in the United States and increasing elsewhere, a trend that has been following since 2015.
Wakame Seaweed Archived 2016-04-21 at the Wayback Machine at About.com AlgaeBase link Undaria pinnatifida Archived 2019-09-24 at the Wayback Machine at the FAO Undaria pinnatifida at the Joint Nature Conservation Committee, UK Global Invasive species database Archived 2011-06-11 at the Wayback Machine Undaria Management at the Monterey Bay National Marine Sanctuary
In turn, these conditions of hypoxia and hypercapnia will trigger additional effects on the body such as Cheyne–Stokes respiration. Some people with sleep apnea are unaware that they have the condition. In many cases, it is first observed by a family member. An in-lab sleep study overnight is the preferred method for diagnosing sleep apnea. In the case of OSA, the outcome that determines disease severity and guides the treatment plan is the apnea-hypopnea index (AHI). This measurement is calculated from totaling all pauses in breathing and periods of shallow breathing lasting greater than 10 seconds and dividing the sum by total hours of recorded sleep. In contrast, for CSA the degree of respiratory effort, measured by esophageal pressure or displacement of the thoracic or abdominal cavity, is an important distinguishing factor between OSA and CSA. A systemic disorder, sleep apnea is associated with a wide array of effects, including increased risk of car crashes, hypertension, cardiovascular disease, myocardial infarction, stroke, atrial fibrillation, insulin resistance, kidney disease, memory loss, neurodegeneration, low testosterone, and higher incidence of cancer. Further research is being conducted on the potential of using biomarkers to understand which chronic diseases are associated with sleep apnea on an individual basis. Treatment may include lifestyle changes, mouthpieces, breathing devices, and surgery. Effective lifestyle changes may include avoiding alcohol, losing weight, quitting smoking, and sleeping on one's side.
The genus Oenococcus has one main member involved in winemaking, O. oeni, once known as Leuconostoc oeni. Despite having the name Oenococcus, under the microscope, the bacterium has a bacillus (shape) rod shape. The bacteria is a Gram-positive, facultative anaerobe that can utilize some oxygen for aerobic respiration but usually produces cellular energy through fermentation. O. oeni is a heterofermenter that creates multiple end products from the use of glucose with D-lactic acid and carbon dioxide being produced in roughly equal amounts to either ethanol or acetate. In reductive conditions (such as near the end of alcoholic fermentation), the third end product is usually ethanol while in slightly oxidative (such as early in alcohol fermentation or in an untopped barrel), the bacteria are more likely to produce acetate. Some O. oeni strains can use fructose to create mannitol (which can lead to wine fault known as mannitol taint), while many other strains can break down the amino acid arginine (which can be present in the wine that is resting on the lees after fermentation from the autolysis of dead yeast cells) into ammonia. In addition to the hexose glucose and fructose sugars, most strains of O. oeni can use the residual pentose sugars left behind from yeast fermentation including L-arabinose and ribose. Only around 45% of O. oeni strains can ferment sucrose (the form of sugar usually added for chaptalization that gets converted by yeast into glucose and fructose). Winemakers tend to prefer O. oeni for several reasons.
Sources: en.wikipedia.org
=== Other studios === After the release of The Avengers in May 2012, Tom Russo of Boston.com noted that aside from the occasional "novelty" such as Alien vs. Predator (2004), the idea of a shared universe was virtually unheard of in Hollywood. Since that time, the shared universe model created by Marvel Studios has begun to be replicated by other film studios that held rights to other comic book characters. In April 2014, Tuna Amobi, a media analyst for Standard & Poor's Equity Research Services, stated that over the previous three to five years, Hollywood studios had begun planning "megafranchises" for years to come, rather than working on one blockbuster at a time. Amobi added, "A lot of these superhero characters were just being left there to gather dust. Disney has proved that this [approach and genre] can be a gold mine." With more studios now "playing the megafranchise game", Doug Creutz, media analyst for Cowen and Company, feels the allure will eventually die for audiences: "If Marvel's going to make two or three films a year, and Warner Brothers is going to do at least a film every year, and Sony's going to do a film every year, and Fox [is] going to do a film every year, can everyone do well in that scenario? I'm not sure they can." In March 2018, Patrick Shanley of The Hollywood Reporter opined that "the key differences between a regular franchise, such as The Fast and the Furious or Pitch Perfect films, and a shared universe is the amount of planning and interweaving that goes into each individual film.
=== Physical properties === Californium is a silvery-white actinide metal with a melting point of 900 ± 30 °C (1,650 ± 50 °F) and an estimated boiling point of 1,743 K (1,470 °C; 2,680 °F). The pure metal is malleable and is easily cut with a knife. Californium metal starts to vaporize above 300 °C (570 °F) when exposed to a vacuum. Below 51 K (−222 °C; −368 °F) californium metal is either ferromagnetic or ferrimagnetic (it acts like a magnet), between 48 and 66 K it is antiferromagnetic (an intermediate state), and above 160 K (−113 °C; −172 °F) it is paramagnetic (external magnetic fields can make it magnetic). It forms alloys with lanthanide metals but little is known about the resulting materials. The element has two crystalline forms at standard atmospheric pressure: a double-hexagonal close-packed form dubbed alpha (α) and a face-centered cubic form designated beta (β). The α form exists below 600–800 °C with a density of 15.10 g/cm3 and the β form exists above 600–800 °C with a density of 8.74 g/cm3. At 48 GPa of pressure the β form changes into an orthorhombic crystal system due to delocalization of the atom's 5f electrons, which frees them to bond. The bulk modulus of a material is a measure of its resistance to uniform pressure. Californium's bulk modulus is 50±5 GPa, which is similar to trivalent lanthanide metals but smaller than more familiar metals, such as aluminium (70 GPa).
Non-diabetics' beta cells routinely and automatically manage this by continual glucose level monitoring and insulin release. All such decisions by a diabetic must be based on experience and training (i.e., at the direction of a physician, PA, or in some places a specialist diabetic educator) and, further, specifically based on the individual experience of the person. But it is not straightforward and should never be done by habit or routine. With some care however, it can be done reasonably well in clinical practice. For example, some people with diabetes require more insulin after drinking skim milk than they do after taking an equivalent amount of fat, protein, carbohydrate, and fluid in some other form. Their particular reaction to skimmed milk is different from other people with diabetes, but the same amount of whole milk is likely to cause a still different reaction even in that person. Whole milk contains considerable fat while skimmed milk has much less. It is a continual balancing act for all people with diabetes, especially for those taking insulin. People with insulin-dependent diabetes typically require some base level of insulin (basal insulin), as well as short-acting insulin to cover meals (bolus also known as mealtime or prandial insulin). Maintaining the basal rate and the bolus rate is a continuous balancing act that people with insulin-dependent diabetes must manage each day.
Svante Cornell argued that although Tagliavini's report did blame Georgia for starting the war, that "should not be confused with the question of responsibility." He also criticised the argument that agreements did not allow Georgia to use force, because the mission did not analyze whether Russian or South Ossetian use of force still bound Georgia to the non-use of force. Cornell also criticised the report since it did not include evidence amassed by researcher Andrey Illarionov. Cornell also wrote in another article that the report was "far more devastating in its dismissal of Russia's justification for its invasion—in fact surprisingly so for an EU product." Georgian president Saakashvili said that the commission "said even more truth than I could ever imagine." He later said that he would still take the same action as he did on 7 August 2008 and he did not regret anything. The report caused the Georgian opposition to protest against President Saakashvili. The Wall Street Journal wrote that the report "shrinks from drawing the obvious conclusion, which is that this is a war the Kremlin wanted, schemed for, and got." On 8 October 2009, NATO Secretary General Anders Fogh Rasmussen declared that the report would not influence Georgian and Ukrainian membership of NATO. On 12 October 2009, Yulia Latynina, Russian journalist, wrote that the commission actually did not establish who was responsible for the war and which of the sides was lying.
Sources: en.wikipedia.org
Animal experiments form the bulk of the published record. Rodent models of tendon, ligament, bone, and gut injury are the most common designs. Controlled human trials are rare, which limits confidence in any clinical claim.
They are best described as working hypotheses. Supporting data come mainly from cell cultures and animal tissue, using markers such as growth factors and inflammatory signals. Confirmatory human studies have not been reported.
Status depends on the country. In some places it is treated as a research chemical available without a prescription, while elsewhere it falls under prescription or controlled rules. It holds no general marketing approval as a therapeutic product.
It is a synthetic peptide of fifteen amino acids whose sequence matches a fragment of a protein found in human gastric juice. It is studied mainly in laboratory and animal research rather than as an approved medicine.